MedTrace Logo

Neurodevelopment at 5.5 Years of Age in Children Who Received Infant Formula With Enriched Protein Fractions

NCT04442477 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 116

Last updated 2021-12-16

No results posted yet for this study

Summary

This is a follow-up study of a multi-center, double-blind, randomized, controlled, parallel-designed, prospective trial and is intended to evaluate neurodevelopment at 5.5 years of age and health outcomes through 5.5 years of age in participants who received one of two staged study formulas through one year of age.

Conditions

  • Cognitive Ability, General

Interventions

DIETARY_SUPPLEMENT

Enriched Protein Fractions

Enriched protein fractions

DIETARY_SUPPLEMENT

Protein Fraction

Protein fractions

Sponsors & Collaborators

  • Mead Johnson Nutrition

    lead INDUSTRY

Principal Investigators

  • Fei Li · Shanghai Children's Medical Center

  • Steven Wu, M.D. · Mead Johnson/RB

Eligibility

Min Age
64 Months
Max Age
68 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-15
Primary Completion
2021-05-27
Completion
2021-05-27

Countries

  • China

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04442477 on ClinicalTrials.gov